Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma.

Purpose: To evaluate the efficacy of intravitreal bevacizumab for prevention of macular edema after plaque radiotherapy of uveal melanoma.

Design: Retrospective, single-center, nonrandomized, interventional comparative study.

Participants: Patients with uveal melanoma treated with plaque radiotherapy were divided into 2 groups: a bevacizumab group and a control group.

Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome.

Purpose: Uveal melanoma (UM) was a fatal malignancy in 40% to 50% of cases. The aim of this study is to evaluate the independent contributions of chromosome 1, 3, 6, and 8 abnormalities for prognostication of metastasis, and to define multichromosome copy number aberration (CNA) signatures that can be used to evaluate risk.

Methods: A series of 320 UM were analyzed for chromosome 1, 3, 6, and 8 abnormalities using whole genome single-nucleotide polymorphism arrays.

Single-agent, minimal dose, minimal exposure intraarterial chemotherapy for retinoblastoma in a 4-month-old infant.

Purpose: To document minimal dose and minimal exposure of chemotherapy for unilateral retinoblastoma.

Methods: A 4-month-old infant developed leukocoria in the right eye and was found to have unilateral sporadic retinoblastoma.

Results: The right eye was classified as Group D retinoblastoma, with a single large tumor, moderate subretinal seeding, and total retinal detachment.

Safety of pars plana vitrectomy in eyes with plaque-irradiated posterior uveal melanoma.

Objective: To determine the long-term safety of pars plana vitrectomy (PPV) in eyes with plaque-irradiated posterior uveal melanoma.

Methods: In this retrospective case series, patients with plaque-irradiated posterior uveal melanoma subsequently underwent PPV for vitreous hemorrhage. The main outcome measures are the rates of intraocular melanoma dissemination, extrascleral extension of melanoma, local melanoma recurrence, and systemic melanoma metastasis after PPV.

Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes.

Purpose: To evaluate the outcomes of iris melanoma managed with plaque radiotherapy on the basis of the initial presence or absence of glaucoma.

Design: Retrospective, comparative case series.

Participants: A total of 144 patients.

Acute exudative paraneoplastic polymorphous vitelliform maculopathy in five cases.

Background And Objective: To evaluate clinical features, course, and outcome of patients with acute exudative paraneoplastic polymorphous vitelliform maculopathy (AEPPVM).

Patients And Methods: Retrospective case series of 5 patients.

Results: There were 3 males and 2 females, with a median age of 74 years.

Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma.

Retinoblastoma is a deadly eye cancer in children, leading to death in 50%-70% of children in undeveloped nations who are diagnosed with it. This malignancy is the most common intraocular tumor in childhood worldwide. The good prognosis in developed nations is related to early detection and advanced treatments.

Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retinoblastoma: long-term results.

Objective: To assess the long-term results of chemotherapy for cavitary retinoblastoma.

Methods: Retrospective, nonrandomized, interventional case series of 26 cavitary retinoblastomas in 25 eyes of 24 patients. Retinoblastomas were treated with intravenous chemoreduction and/or intra-arterial chemotherapy.

Sector laser photocoagulation for the prevention of macular edema after plaque radiotherapy for uveal melanoma: a pilot study.

Objective: To investigate the role of sector laser photocoagulation for prevention of macular edema after plaque radiotherapy for uveal melanoma.

Methods: Noncomparative, pilot interventional case series. The main outcome measure was optical coherence tomography-evident macular edema.

Intravenous and intra-arterial chemotherapy for retinoblastoma: what have we learned?

Purpose Of Review: To review the recent literature on two methods of chemotherapy for retinoblastoma using intravenous versus intra-arterial route.

Recent Findings: In 1996, the era of intravenous chemotherapy (chemoreduction) for retinoblastoma was introduced with major centers providing published information on impressive tumor control, without the need for external beam radiotherapy or enucleation. Later reports heralded continued impressive long-term control, minimal systemic toxicities, likely prevention of pinealoblastoma (trilateral retinoblastoma), and reduction in numbers of germline mutation second cancers.

Combined hamartoma of the retina and retinal pigment epithelium in a child with branchial cleft cysts.

An otherwise healthy 15-month-old boy presented with benign branchial cleft cysts and combined hamartoma of the retina and retinal pigment epithelium. This association was previously only reported in a patient with branchio-oculo-facial syndrome. Although uncommon, this could represent multifocal sites of fetus craniofacial malformation.

Effect of intraarterial chemotherapy on retinoblastoma-induced retinal detachment.

Purpose: To study the effect of intraarterial chemotherapy (IAC) on retinoblastoma-induced retinal detachment.

Methods: Retrospective, noncomparative, interventional case series including 15 patients, with intraarterial (ophthalmic artery) chemotherapy as the intervention. Resolution of retinal detachment was the main outcome measure.

Clinical survey of 3680 iris tumors based on patient age at presentation.

Objective: To report the spectrum of iris lesions based on patient age at presentation.

Design: Retrospective, nonrandomized, single-center case series.

Participants: We included 3680 iris tumors in 3451 patients.

Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma.

Purpose: To assess the efficacy of less than 3 cycles of intra-arterial chemotherapy (IAC) for retinoblastoma.

Design: Retrospective, nonrandomized, interventional case series.

Participants: Eight patients.

Presumed solitary circumscribed retinal astrocytic proliferation: the 2010 Jonathan W. Wirtschafter Lecture.

Objective: To report the clinical features and differential diagnosis of an unusual entity termed presumed solitary circumscribed retinal astrocytic proliferation (PSCRAP).

Methods: Retrospective review of medical records.

Results: All patients with PSCRAP were asymptomatic, and the lesion was found during routine examination.

Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds.

Objective: To describe tumor control following intra-arterial chemotherapy (IAC) for retinoblastoma.

Methods: A retrospective interventional series in which 17 patients were treated with ophthalmic artery injection of melphalan, 5 mg, was undertaken to determine retinoblastoma control.

Results: Of 190 children with retinoblastoma, 17 (9%) were treated with IAC.

Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications.

Objective: To describe treatment complications following intra-arterial chemotherapy (IAC) for retinoblastoma.

Methods: A retrospective interventional series of ophthalmic artery cannulation for IAC injection (3 planned sessions at 1-month intervals) was undertaken. Thirty-eight catheterizations of 17 eyes of 17 patients were performed from September 2008 to September 2010.

Complete regression of retinoblastoma following intra-arterial chemotherapy.

A 22-month-old girl with Group C unilateral retinoblastoma demonstrated dramatic tumor regression after two infusions of 5 mg of intra-arterial melphalan as primary therapy. Complete tumor control without recurrence was noted at 1 year. Retinal and choroidal perfusion was intact and the electroretinogram improved following therapy.

Ocular surface squamous neoplasia (squamous cell carcinoma) of the socket: management of extensive tumors with interferon.

Purpose: To describe the clinical features and management of extensive ocular surface squamous neoplasia (OSSN) (squamous cell carcinoma) of the socket.

Methods: Retrospective interventional case series. Interferon α 2b (IFNa2b) eye drops (1 million units/cc) 4 times daily and IFNa2b sublesional injection (5 million units/0.

Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens.

Purpose: To determine the relationship between monosomy 3 and incidence of metastasis after genetic testing of uveal melanoma using fine-needle aspiration biopsy (FNAB).

Design: Noncomparative retrospective case series.

Participants: Five hundred patients.

Topical imiquimod for periocular lentigo maligna.

Purpose: To evaluate the efficacy of topical imiquimod 5%, a local immune response modifier, in the treatment of periocular lentigo maligna.

Design: Retrospective, interventional case series.

Participants: Five consecutive patients with biopsy-proven periocular lentigo maligna.

Simultaneous eyelid and choroidal metastases 36 years after diagnosis of medullary thyroid carcinoma.

A 56-year-old man had a 6-month history of a progressively enlarging mass of his right upper eyelid. Thirty-six years previously he had undergone thyroidectomy for medullary thyroid carcinoma in the absence of family history. Supraclavicular lymph node metastases were discovered 3 years after initial diagnosis, pulmonary metastasis 26 years later, and cervical lymph node metastases 35 years later.